Vaccine Prevented Cervical Pre-Cancers, Non-Invasive Cancers In Phase III Trial
SWOG Seeks NSCLC Patients For Study Of Gender Differences In Lung Cancer
NCI Begins Ovarian Cancer Trial To Build Blood Samples
Aromasin Approved By FDA For ER+ Early Breast Cancer
NSAIDs Cut Oral Cancer Risk But Raise Smokers’ Heart Risk
HRT Doesn’t Raise Cancer Risk Following Oophorectomy
Obesity, Faster Weight Gain, Linked To Poor Prognosis
Study Finds Up To 12 Percent Of Specimens Misdiagnosed
NCI Cooperative Group, Cancer Center Trials Listed
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
